China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE: 300294)

Market Cap	16.81B
Revenue (ttm)	2.01B
Net Income (ttm)	227.52M
Shares Out	504.25M
EPS (ttm)	0.45
PE Ratio	74.03
Forward PE	28.61
Dividend	0.30 (0.90%)
Ex-Dividend Date	Apr 26, 2024

Volume	2,424,100
Open	33.49
Previous Close	33.28
Day's Range	33.21 - 34.19
52-Week Range	22.91 - 36.64
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About China Resources Boya Bio-pharmaceutical Group Co.,Ltd

China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible ta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 1,444
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300294

Financial Performance

In 2023, China Resources Boya Bio-pharmaceutical Group Co.,Ltd's revenue was 2.65 billion, a decrease of -3.87% compared to the previous year's 2.76 billion. Earnings were 237.47 million, a decrease of -45.06%.